Clopidogrel in secondary ischemic stroke prevention.

Abstract

The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD). Clopidogrel showed a similar efficacy and safety than acetylsalicylic acid (ASA). More recently, the combined use of clopidogrel with ASA has evidenced a better protection than ASA alone in some patients: patients with past history of AMI, angina pectoris, intermittent claudication or PAD, IS or TIA, coronary bypass, and diabetes mellitus, patients on treatment with statins, and patients with symptomatic carotid stenosis >/=50%. We review the reported evidence on the efficacy of clopidogrel in the secondary prevention of ischemic stroke.

• Authors: Robert Belvís, Javier Pagonabarraga, Amparo Santamaría, Jaime Kulisevsky
• Journal: Recent patents on cardiovascular drug discovery (Recent Pat Cardiovasc Drug Discov) Vol. 3 Issue 2 Pg. 119-25 (Jun 2008) United Arab Emirates
• PMID: 18537762 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Aggregation Inhibitors
• Clopidogrel
• Ticlopidine
• Aspirin

Topics

• Aspirin (therapeutic use)
• Brain Ischemia (complications, drug therapy, pathology)
• Clinical Trials as Topic
• Clopidogrel
• Drug Therapy, Combination
• Evidence-Based Medicine
• Humans
• Patient Selection
• Platelet Aggregation Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Practice Guidelines as Topic
• Risk Assessment
• Risk Factors
• Secondary Prevention
• Stroke (drug therapy, etiology, pathology)
• Thrombolytic Therapy
• Ticlopidine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Treatment Outcome